CB6-LALA is a neutralizing mAb isolated from B cells from the CP of patients with COVID-19, and it blocks the binding between the SARS-CoV-2 RBD and hACE2 through steric hindrance and competition for the interface amino acid interaction, without inducing conformational changes in the RBD. The gene discussed is CP; the disease is COVID-19.